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The lengthy duration of multidrug therapy needed to cure tuberculosis (TB) poses 
significant challenges for global control of the disease. Moreover, chronic inflammation 
associated with TB leads to pulmonary damage that can remain even after successful 
cure. Thus, there is a great need for the development of effective shorter drug regimens 
to improve clinical outcome and strengthen TB control. Host-directed therapy (HDT) 
is emerging as a novel adjunctive strategy to enhance the efficacy and shorten the 
duration of TB treatment. Previously, we showed that the administration of CC-3052, a 
phosphodiesterase-4 inhibitor (PDE4i), reduced the host inflammatory response during 
Mycobacterium tuberculosis (Mtb) infection and improved the antimicrobial efficacy of 
isoniazid (INH) in both the mouse and rabbit models. In the present study, we evaluated 
the pharmacokinetics and explored the mechanism underlying the efficacy of a more 
potent PDE4i, CC-11050, as adjunct to INH treatment in a mouse model of pulmonary 
Mtb infection. Genome-wide lung transcriptome analysis confirmed the dampening of 
inflammation and associated network genes that we previously reported with CC-3052. 
Consistent with the reduction in inflammation, a significant improvement in Mtb control 
and pathology was observed in the lungs of mice treated with CC-11050 plus INH, 
compared to INH alone. This important confirmatory study will be used to help design 
upcoming human clinical trials with CC-11050 as an HDT for TB treatment.
Keywords: Mycobacterium tuberculosis, immune modulation, phosphodiesterase-4 inhibitor, mouse model, 
pulmonary tuberculosis, gene expression, host-directed therapy
inTrODUcTiOn
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is a leading killer among infectious 
diseases, accounting for 1.5 million deaths and an estimated 9.6 million new cases in 2014.1 
Standard short-course chemotherapy for pulmonary TB involves directly observed administra-
tion of four antibiotics, isoniazid (INH), rifampicin (RIF), ethambutol (EMB), and pyrazinamide 
(PZA) for 2  months, followed by INH and RIF therapy for 4  months (1). The long duration 
1 http://www.who.int/tb/Global_TB_Facts.pdf?ua=1
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of treatment presents difficulties for case management and 
adherence, especially among patients from the poverty-stricken 
communities that are most affected. Inadequate therapy or 
treatment interruptions greatly elevate the risks of relapse and 
acquisition of drug resistance, thereby increasing the potential 
for further transmission and limiting therapeutic options for 
the patient. Moreover, residual lung damage and an elevated 
risk of reinfection can remain even after successful cure of TB 
(2–4). To overcome these problems, there is a great need for the 
development of effective shorter drug regimens to improve clini-
cal outcome and enhance TB control. However, thus far, efforts 
to shorten TB chemotherapy have proven unsuccessful (5). This 
was most recently demonstrated in a series of randomized 
controlled clinical trials, showing that substitution of INH or 
EMB by one of the newer fluoroquinolones in a short-course 
regimen administered for 4 months led to an increased incidence 
of relapse, compared to the standard 6-month drug regimen (6).
Host-directed therapy (HDT) as an adjunct to conventional 
antibiotic regimens is emerging as a novel strategy for shorten-
ing the duration of TB therapy (7, 8). An important advantage 
of this approach is that Mtb cannot develop resistance to drugs 
that target host cell functions. Evidence from both in vitro and 
in vivo studies suggests that the extended duration of TB therapy 
necessary to achieve cure may be explained by an ability of the 
bacilli to shift to a slow or non-replicating state, in which they 
are not responsive to standard doses of the currently available 
antibiotics (5, 9). Non-replicating persistence of Mtb has been 
associated with diverse environmental pressures exerted by the 
host immune response, including hypoxia and the production of 
reactive nitrogen intermediates, which are capable of driving the 
bacilli toward a dormant phenotype in vitro (10).
Based on these reports, we hypothesized that dampening the 
inflammatory response, which is associated with macrophage 
activation and the environmental pressure on intracellular Mtb, 
through the use of adjunctive HDT, could render the bacilli more 
vulnerable to antibiotic-mediated killing. We have demonstrated 
the value of this approach by showing, in both the mouse and 
rabbit models, that adjunctive treatment with the small molecule 
phosphodiesterase-4 inhibitor (PDE4i), CC-3052, reduced the 
overt inflammatory response during Mtb infection and signifi-
cantly improved INH-mediated bacillary clearance from the lungs 
(11–13). While the PDE4i alone had no impact on the growth of 
Mtb in  vitro, within the lungs of CC-3052-treated animals, we 
observed a significant reduction in the expression of several Mtb 
stress response genes that are associated with dormancy (12). In 
addition, we noted changes in the pathologic manifestations of 
lung granulomas in both mice and rabbits in response to CC-3052. 
The reduction in pathology induced by PDE4 inhibition in the 
Mtb-infected lungs indicates that this treatment strategy may 
help to limit pulmonary damage for improved clinical outcome 
in TB patients.
The present study was undertaken to compare the impact of 
CC-3052 in the murine TB model with a second PDE4i (CC-
11050), in preparation for a clinical trial of the latter drug in TB 
patients. CC-11050 shows improved stability over CC-3052, has 
demonstrated safety in humans, and has progressed to a phase II 
clinical trial for treatment of lupus erythematosus and a phase I 
trial in HIV-infected adults on antiretroviral therapy. To better 
understand the underlying molecular events associated with 
PDE4 inhibition during TB chemotherapy, we recently studied 
CC-11050 as an adjunct to INH treatment in the rabbit model 
of pulmonary TB. We showed that CC-11050 reduced inflam-
mation and pathology in the lungs and increased the antibiotic 
responsiveness of the infecting Mtb (14). Here, we describe the 
pharmacokinetics of CC-11050 in mice and show that the drug 
reduces the inflammatory response and improves INH-mediated 
bacillary clearance from the lungs. Taken together, the results of 
our studies indicate that CC-11050 is a promising candidate for 
HDT that may shorten the duration of treatment and improve 
clinical outcome in patients with pulmonary TB.
MaTerials anD MeThODs
Bacterial growth and chemicals
Mycobacterium tuberculosis CDC1551 was grown in Middlebrook 
7H9 media (BD Biosciences, MD, USA) as described in Ref. (11). 
CC-11050 was provided by Celgene Corporation, Summit, NJ, 
USA. All other chemicals were purchased from Sigma (Sigma–
Aldrich, MO, USA), unless stated otherwise.
animal Welfare and ethical statement
Eight-week-old female B6D2F1 mice (The Jackson Laboratory, 
Bar Harbor, ME, USA) were used in this study. All animal 
procedures, including aerosol infection, oral gavage treatment, 
postinfection/treatment monitoring, were performed following 
standard protocols approved by the Institutional Animal Care 
and Use Committee (IACUC) of Rutgers University and were 
in compliance with institutional and governmental guidelines 
regulating the care and use of laboratory animals in experimental 
research.
structure and In Vivo Pharmacokinetics 
of cc-11050
The PDE4i, CC-11050 (N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)- 
2-(methylsulfonyl) ethyl]-2,3-dihydro-3-oxo-1H-isoindol-4-yl]- 
(9Cl) cyclopropanecarboxamide) has an empirical formula of 
C24H28N2O6S with one chiral center (Figure S1A in Supplementary 
Material). Uninfected mice (n = 3 per group) were treated with 5, 
25, or 50 mg/kg of CC-11050 by oral gavage. In another experi-
ment, mice (n = 3) were treated with 50 mg/kg of CC-11050 plus 
50 mg/kg of INH. A group of mice (n = 3) without treatment 
were included as negative control. Venous blood was collected 
at 1, 2, 5, 8, and 24  h after a single gavage administration of 
CC-11050, with or without INH. Time-matched blood samples 
were also collected from untreated mice. The animals were gav-
aged after overnight fasting and fed soon after gavage. Plasma 
was collected by centrifugation of blood samples at 1,100× g for 
10 min at 10°C and used for LC-MS/MS analysis.
The standard curve and quality control for CC-11050 were 
prepared in mouse plasma diluted 1:1 with Sorenson’s Citrate 
Buffer (25  mM; pH 1.5). Internal standard was prepared with 
13CD3-CC-11050 and mixed with the standard, quality control, or 
test samples at 4:1:1 (13CD3-CC-11050:mouse plasma:Sorenson’s 
3Subbian et al. Immunotherapy for Tuberculosis
Frontiers in Immunology | www.frontiersin.org June 2016 | Volume 7 | Article 238
Citrate Buffer, vol/vol/vol) ratio. The mix was centrifuged at 
4,000  rpm for 10  min at room temperature, and the superna-
tant was transferred to a 96-well assay plate. LC-MS/MS was 
performed using a Sciex API 4000 triple quadrupole mass 
spectrometer (Sciex, Division of MDS Inc., Canada) coupled to a 
Shimadzu HPLC system (Shimadzu Scientific Instruments, MD, 
USA). A Phenomenex Gemini column (5 μm, 2.0 mm × 50 mm; 
Phenomenex, CA, USA) was used for chromatography with 0.1% 
formic acid in water (mobile phase A) and 0.1% formic acid in 
acetonitrile (mobile phase B). The parameters used were 0 min 
for 10%B, 0.0–2.0  min for 10–75%B, 2.1–3.0  min for 95%B, 
and 3.05–4.0 min for 10%B. For mass spectrometric detection, 
a positive ion mode with turbo spray (ion source temperature 
of 450°C) and a dwell time of 100 ms was used. Analytes were 
quantified using multiple reactions monitoring (MRM) at the 
following transitions: mass-to-charge ratio 473.1–178.1 and 
477.1–182.1 m/z for CC-11050 and its internal standard, respec-
tively. Peak area ratios of the analyte to its internal standard versus 
analyte concentration, represented as quadratic regression plots, 
were derived with 1/x2 weighting. Watson LIMS™ software was 
used to determine the pharmacokinetic parameters (Thermo 
Fisher, PA, USA). Peak plasma concentration (Cmax) and corre-
sponding time (Tmax) were calculated from raw data. Area under 
the plasma concentration-time curve (AUC) was determined by 
linear/linear-log trapezoidal rule of non-compartmental model 
using data from time 0 and the last measurable time point 
(AUClast). All statistics were performed with Watson LIMS™ 
software. Plasma concentrations below the limit of quantitation 
(BLOQ) were treated as 0 for calculation.
aerosol infection of Mice and estimation 
of Bacterial load
Female B6D2F1 mice were infected with Mtb CDC1551 using 
an aerosol-exposure system (CH Technologies Inc., Westwood, 
NJ, USA), as described in Ref. (11). The infection inoculum 
was adjusted to implant 100–150 bacterial colony-forming 
units (CFUs) in the lungs. To determine the actual number of 
bacilli inoculated, Mtb-infected mice (n =  6) were euthanized 
3  h postinfection (T =  0), and serial dilutions of whole lung 
homogenates, prepared in sterile 1×PBS, were plated on 
Middlebrook 7H11 agar (Difco Laboratories Inc., Detroit, MI, 
USA); CFUs were counted following 4–6 weeks of incubation at 
37°C in 5% CO2. Mtb-infected mice (n = 6) were euthanized at 
14 days postinfection to determine the lung bacillary load (CFU) 
and pathology at the time of initiating treatment. At 14  days 
postinfection, Mtb-infected mice were allocated into four groups 
(n  =  24 per group) and treated with CC-11050 (50  mg/kg), 
INH (50 mg/kg), or CC-11050 plus INH. The fourth group of 
Mtb-infected mice was left untreated as control. All drugs were 
dissolved in water and administered daily through oral gavage. 
At 28, 56, 84, and 112 days postinfection, mice from each group 
(n = 5–6 per group per time point) were euthanized, and portions 
of the lungs were used to prepare homogenates for CFU assay, 
stored in formalin for histologic analysis, or frozen immediately 
for RNA isolation. Serial dilutions of lung homogenates from 
these time points were plated on 7H10 agar supplemented with 
0.2 or 1 μg/ml of INH to test for the emergence of INH-resistant 
Mtb; no CFUs were detected.
histologic analysis
Formalin-fixed lung tissues of Mtb-infected mice were paraffin-
embedded, cut into 5 μg sections, and stained with hematoxylin 
and eosin (H&E) or acid fast staining by Ziehl–Neelsen (ZN) 
method to visualize host cells and Mtb, respectively (IDEXX-
RADIL Laboratories Inc., MO, USA) as described in Ref. (11). 
Stained sections were photographed in a Nikon Microphot-FX 
photomicrographic system and analyzed with NIS-Elements 
F3.0 software (Nikon Instruments Inc., NY, USA). Lung granu-
loma size was morphometrically measured using PathScan 
Enabler IV scanner (Meyer Instruments, Houston, TX, USA) 
and SigmaScan Pro software (Systat Software, Inc., CA, USA). 
Histopathologic analysis and morphometry were performed by 
an experienced pathologist blinded to the sample identity.
rna isolation and Microarray analysis
Total RNA was isolated from the lungs of uninfected or Mtb-
infected mice with or without CC-11050 treatment (n =  4 per 
group) after 14 days of treatment using Trizol reagent (Invitrogen, 
CA, USA) as described in Ref. (11). One microgram of total lung 
RNA from each mouse was individually processed for cDNA 
synthesis using SuperScript II system (Agilent Technologies, 
CA, USA). The microarray experiment was performed using 
mouse genome ST 1.0 microarray kit (Affymetrix, Santa Clara, 
CA, USA), following a standard protocol2 for the data extraction 
and analysis. RMA-normalized, log2-transformed array data 
from individual mice from each group (n = 4 per group) were 
compared as follows (i) Mtb-infected versus uninfected and (ii) 
Mtb-infected CC-11050-treated versus untreated, using ANOVA 
in Partek Genomics Suite (Partek Inc., St. Louis, MO, USA). 
Significantly differentially expressed genes (SDEGs) were identi-
fied using 5% false discovery rate (FDR). The list of SDEGs was 
further analyzed using QIAGEN’s Ingenuity® Pathway Analysis 
(IPA®-QIAGEN, CA, USA) to determine significantly enriched 
(P < 0.05) gene networks and canonical pathways as described 
in Ref. (15). The microarray data has been submitted to GEO 
(Accession number GSE83188).
Quantitative real-time Pcr
Total lung RNA (200 ng) was reverse-transcribed using Sprint RT 
kit (Clontech, CA, USA); 10 ng of cDNA were used for quantita-
tive real-time PCR (qPCR), with Brilliant II SYBR master mix 
(Agilent Technologies, CA, USA) and gene-specific primers in 
a Stratagene Mx3005P instrument (Agilent Technologies, CA, 
USA). ROX was included in each reaction as an internal con-
trol. The qPCR assay was performed using four mouse samples 
in duplicate per group; the data were analyzed using MxPro 
Software (Agilent Technologies, CA, USA). Transcript levels of 
Gapdh were used as a reference against the test genes. Fold change 
in gene expression was calculated using the formula 2−ΔΔCt, where 
2 http://www.cag.icph.org/index.htm
TaBle 1 | Plasma levels of cc-11050 with or without inh in mice after a 
single oral dose.
sampling time (h) concentration (ng/ml)a
cc-11050 only cc-11050 + inh
1 1,331.6 ± 136.97 905.35 ± 594.23
2 1,409.47 ± 140.85 1,309.39 ± 214.08
5 948.85 ± 128.7 1,609.18 ± 167.2
8 820.6 ± 265.98 1,271.73 ± 249.18
24 1.27 ± 1.1 4.96 ± 1.85
Tmax (h) 2.0 5.0
Cmax (ng/ml) 1,410 1,610
AUClast (ng × h/ml) 10,200 13,900
aValues shown are mean ± SD.
FigUre 1 | expression of host PDe4 genes in Mtb-infected untreated 
(hatched bars) or cc-11050-treated (solid bars) mouse lungs, relative 
to the uninfected controls. Experiment was performed in duplicate with 
four biological replicates (n = 4 per group). *P = 0.0037 for Pde4D and 
P = 0.015 for Pde4Bi3 between untreated and CC-1150-treated groups.
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ΔCt is the difference in threshold cycle (Ct) between the target 
gene and Gapdh; and ΔΔCt is the ratio between untreated and 
CC-11050-treated samples. Primers were designed based on 
nucleotide sequences obtained from PrimerBank.3
statistical analysis
Student’s t-test in GraphPad Prism (GraphPad Software, CA, 
USA) was used to analyze group-wise comparisons of the CFUs, 
qPCR, and morphometric data. P < 0.05 was considered statisti-
cally significant. ANOVA in Partek Genomic Suite version 6.6 
was used for microarray gene expression analysis, and right-
tailed Fisher’s exact test in ingenuity pathway analysis was used 
to determine the significance for pathway/network analysis as 
described in Ref. (15).
resUlTs
Pharmacokinetics of cc-11050
A single oral administration of CC-11050 at each of three dose 
levels (5, 25, 50  mg/kg) demonstrated rapid absorption of the 
drug, with peak plasma concentrations reached by 1–2 h (Tmax) 
(Figure S1B in Supplementary Material). The average composite 
exposures of CC-11050, measured by area under the curve 
(AUClast) in the plasma of mice given 5, 25, and 50 mg/kg doses, 
were 1,080, 2,800, and 10,200 ng × h/ml, respectively. As com-
pared to the response to a single oral dose of CC-11050 (50 mg/
kg) alone, CC-11050 (50 mg/kg) given in combination with INH 
(50 mg/kg), resulted in a delayed Tmax from 2 to 5 h (Table 1). 
In addition, a slight increase in the maximum plasma concentra-
tion of CC-11050 (Cmax) was noted in mice treated with CC-11050 
plus INH, compared to CC-11050 alone (1,610 versus 1,410 ng/
ml). Moreover, the AUClast for mice treated with CC-11050 plus 
INH was slightly higher than for those treated with CC-11050 
alone (13,900 versus 10,200 ng × h/ml, respectively).
cc-11050 Treatment reduces Pde4 
expression in Mtb-infected Mouse lungs
To test the impact of CC-11050 treatment on the expression 
pattern of Pde4, qPCR was performed using total RNA from 
the lungs of uninfected, Mtb-infected, and CC-11050-treated or 
3 https://pga.mgh.harvard.edu/primerbank/
untreated mice 14 days after initiation of treatment (i.e., 28 days 
postinfection) (Figure 1). Compared to the uninfected controls, 
Mtb infection induced the expression of all five genes tested in the 
lungs. Among these, CC-11050 treatment significantly reduced 
the expression level of Pde4D (P = 0.0037) and Pde4Bi3 (Pde4B 
isoform 3; P =  0.015). No significant change in the expression 
of Pde4A, Pde4Bv3 (Pde4B variant 3), and Pde4C was noted 
(Figure 1). Taken together, these results suggest that Pde4D and 
Pde4Bi3 are potential targets of CC-11050, although this observa-
tion needs to be confirmed at the protein level.
genome-Wide lung Transcriptome 
analysis of Untreated and cc-11050-
Treated Mtb-infected Mice
A microarray-based global gene expression profiling was used 
to determine the effect of CC-11050 treatment on Mtb-infected 
mouse lungs at 14  days of treatment. Principal component 
analysis (PCA) of the normalized data shows distinct clustering 
of the uninfected and Mtb-infected with or without CC-11050 
treatment groups (Figure 2A). The PCA map also shows that the 
median expression level (±2SD) data within individual groups 
segregate closely and far from the other groups. This observation 
shows a high level of reproducibility of variables (state of infec-
tion and treatment) within and between the data obtained from 
different groups. With an FDR of 5% applied to the array data, we 
found 5,850 SDEGs in the lungs of Mtb-infected mice, relative to 
uninfected controls. In the Mtb-infected CC-11050-treated mice, 
1,277 SDEGs were observed, relative to the infected untreated 
animals. Of these, 861 SDEGs were shared between the treated 
and untreated Mtb-infected groups (Figure 2B). Among the total 
genes, the expression of 875 SDEGs (685 upregulated and 190 
downregulated) in the untreated and 47 SDEGs (29 upregulated 
and 18 downregulated) in the CC-11050-treated group were 
affected by more than 1.5-folds. Taken together, the microarray 
data suggest that Mtb infection significantly affects the expression 
of thousands of host genes in the lungs. Of these, the expres-
sion of a subset of these (14.7%) was significantly affected in 
FigUre 2 | genome-wide lung transcriptome of Mtb-infected mice 
with or without cc-11050 treatment. (a) Principal component analysis 
(PCA) map showing segregation of uninfected, Mtb-infected untreated, or 
CC-11050-treated samples (n = 4 per group). The eclipse/oval shape 
represents 2 × SD from the mean data. (B) Venn diagram showing unique 
and shared SDEGs between Mtb-infected untreated (red) and CC-11050-
treated (blue) mouse lungs after 14 days of treatment. A false discovery rate 
(FDR) of 5% was applied to select the SDEGs. Microarray data were 
generated with four biological replicates per each group. Numbers in 
parenthesis are the total SDEGs.
TaBle 2 | gene ontology analysis of significantly differentially expressed 
genes.
Biological function P value
Mtb-infected untreated versus uninfected
Infectious disease 8.36E−34–4.77E−08
Immunological disease 4.51E−31–1.36E−07
Inflammatory response 7.45E−31–2.26E−08
Cellular function and maintenance 8.82E−48–1.08E−07
Cellular growth and proliferation 8.54E−34–1.12E−07
Cell death and survival 1.03E−33–6.24E−08
Cellular movement 5.24E−33–1.27E−07
Cellular development 2.52E−32–1.12E−07
cc-11050-treated versus untreated
Infectious disease 8.53E−05–1.64E−02
Gene expression 1.47E−06–1.80E−02
Cellular assembly and organization 2.65E−05–2.38E−02
Cell morphology 6.44E−05–2.38E−02
Cellular growth and proliferation 8.73E−05–2.29E−02
Cellular function and maintenance 1.02E−04–2.38E−02
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the CC-11050-treated infected mice. Selected SDEGs from the 
microarray, including Cyp10, Ly6a, Trdn, Irg1, Cxcl10, Ifng, 
and Tnfa, were confirmed by qPCR. As shown in Figure S2 in 
Supplementary Material, the expression pattern of these genes 
was consistent between microarray and qPCR.
gene Ontology analysis of sDegs
To determine the biological functions affected by the differen-
tial host gene expression in the Mtb-infected untreated and 
CC-11050-treated mouse lungs, we analyzed respective sets of 
SDEGs using IPA (Table  2). The gene ontology (GO) analysis 
revealed that host cell processes associated with infectious disease 
and inflammatory response were among the most significantly 
affected biological functions in the Mtb-infected untreated 
group. This is consistent with the progressive pathology seen in 
the mouse lungs (see below). In the infected CC-11050-treated 
animals, biological functions associated with infectious disease, 
gene expression, and host cell assembly and organization were 
among the most significantly affected. As shown in Table 2, the 
biological functions affected in the untreated group were of a 
higher level of significance (10−34–10−07), compared to a moderate 
level of significance for the CC-11050-treated group (10−06–10−02). 
Taken together, the GO analysis suggests distinct changes in the 
biological functions affected in the mouse lungs by Mtb infection 
with or without CC-11050 treatment.
selected immune network/Pathway 
analysis of sDegs
Based on the GO results, we extended our analysis to explore 
the TNF-α interaction, lung inflammatory response, Il-17, and 
interferon (Ifn) signaling networks/pathways. These networks/
pathways play key roles in the host immune/inflammatory 
response to Mtb infection and are likely to be affected by the 
anti-inflammatory activities of PDE4 inhibitors (16). The expres-
sion pattern of selected SDEGs in these networks/pathways was 
validated by qPCR (Figure S2 in Supplementary Material).
TNF-α Interaction Network
Among the SDEGs in the Mtb-infected untreated mouse lungs, 
479 were associated with the TNF-α interaction network. Of 
these, 246 genes were upregulated, including 51 genes induced 
by more than twofold, while 234 genes were downregulated 
(Figure 3A; Table S1 in Supplementary Material). The expression 
of TNF-α-mediated inflammatory molecules, including Cxcl9, 
Saa2, Cxcl10, and Irg1 (Table S1 in Supplementary Material), was 
upregulated by more than 10-fold in the Mtb-infected untreated 
FigUre 3 | intensity plot of TnF-α (a) and lung inflammatory response 
(B) network gene expression in Mtb-infected mouse lungs with or 
without cc-11050 treatment. UT, untreated; CC, treated with CC-11050. 
Only genes expressed in CC are shown in italicized gene symbols. Red color 
shows upregulation and blue color shows downregulation of gene 
expression. Scale bar ranges from +3 (red) to −3 (blue).
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animals. Compared to this, 33 SDEGs were upregulated, and 8 
SDEGs were downregulated in the lungs of CC-11050-treated 
infected animals (Figure  3A; Table S1 in Supplementary 
Material). In these animals, none of the SDEGs was altered by 
more than a twofold change in expression. Thus, CC-11050 treat-
ment significantly dampened the expression of many SDEGs in 
the TNF-α network that were upregulated in response to Mtb 
infection in the mouse lungs.
Lung Inflammation Network
TNF-α is one of the key proinflammatory molecules involved 
in driving the host inflammatory response during progressive 
TB (16). Therefore, we investigated the expression profile of 
the lung inflammation network in the Mtb-infected untreated 
and CC-11050-treated mouse lungs (Figure  3B; Table S1 in 
Supplementary Material). To avoid repetition, SDEGs analyzed 
in the TNF-α interaction network were excluded from the list of 
genes included in the lung inflammation network. A subset of 
137 out of 5,780 SDEGs in the infected untreated mouse lungs 
were associated with the inflammatory response. Of these, 95 
genes were upregulated, including I11β, Il6, Mmp14, Ccr5, Nos2, 
Mcp1, Stat1, and Cxcr3, while 42 genes were downregulated. In 
comparison, nine genes were upregulated, and four were down-
regulated in the infected CC-11050-treated animals (Figure 3B; 
Table S1 in Supplementary Material). Thus, consistent with the 
expression pattern of the TNF-α network, many of the SDEGs in 
the inflammatory response were upregulated by Mtb infection. 
These results suggest that CC-11050 dampened the expression of 
key inflammatory response molecules triggered by Mtb infection 
in the treated mouse lungs.
Il-17 Interaction Network
Recently, Il-17 has been implicated as a crucial cytokine in 
the host immune/inflammatory response to Mtb infection 
(17). We probed the SDEGs from Mtb-infected untreated and 
CC-11050-treated mouse lungs to examine the differential 
expression of genes associated with Il17. Of the total SDEGs, 
30 genes were found to be associated with the Il-17 interaction 
network. Of these, Mtb infection resulted in upregulation of 20 
genes, including Nos2, Ifnγ, Ccl13, Tnfα, and Ccl5, which were 
induced by more than twofold, and downregulation of 9 genes 
(Figures  4A,B). In the infected untreated animals, Il17D was 
downregulated, while no significant change was noted in Il17A 
and Il17F expression. In contrast, only four genes (HmgB1, Il17F, 
Entpd1, and HspB8) were significantly differentially expressed in 
the lungs of infected CC-11050-treated mice; all of which were 
affected by less than twofold (Figure  4B). In summary, while 
97% of genes in the Il-17 interaction network were significantly 
affected by Mtb infection, the expression of 87% of these genes 
was dampened by CC-11050, suggesting downregulation of this 
network in the infected treated mouse lungs.
Canonical IFN Signaling Pathway
Interferon signaling is a hallmark of the onset of the adap-
tive immune response to Mtb infection in mouse lungs (16). 
As expected, many genes in this pathway, including Ifnγ, Stat1, 
Stat2, Irf1, Irf9, Ifi35, and Ifit3, were upregulated in the mouse 
lungs by Mtb infection (Figures 5A,B). However, in the infected 
CC-11050-treated animals, with the exception of Ifngr3 that was 
downregulated, the expression of all other genes in this pathway 
remained at levels similar to uninfected controls (Figure  5B; 
Table S1 in Supplementary Material).
cc-11050 Plus inh Treatment 
reduces Bacillary load in  
Mtb-infected Mouse lungs
To determine the impact of CC-11050 on treatment of Mtb-
infected mice with INH, we enumerated the lung bacillary load 
in all treatment groups over the duration of infection (Figure 6). 
The inoculum at time 0 (3 h postinfection) was about 2 log10 CFU. 
At  the onset of treatment (14 days postinfection), the bacillary 
FigUre 4 | gene interaction network and intensity plot of sDegs associated with il-17 in Mtb-infected mouse lungs with or without cc-11050 
treatment. (a) Interaction of member genes involved in Il-17 expression/regulation. Solid lines represent direct connection, and broken lines indicate  
indirect link. Red color indicates upregulation, and green color depicts downregulation. (B) Intensity plot of SDEGs associated with Il-17 network. UT,  
untreated; CC, treated with CC-11050. Red color shows upregulation, and blue color denotes downregulation of gene expression. Scale bar ranges from  
+3 (red) to −3 (blue).
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load had reached 4.2 log10 CFU. In mice left untreated or treated 
with CC-11050 alone, the bacillary load increased to about 5.5 
log10 by 28  days and remained at persistently high levels until 
112 days postinfection in both groups (Figure 6A). No signifi-
cant difference in the number of lung CFUs was noted between 
untreated and CC-11050-treated mice at any of the time points 
tested, indicating that CC-11050 does not have anti-Mtb activ-
ity and does not cause generalized immune suppression in the 
animals. In the mice treated with INH or INH plus CC-11050, 
we observed a gradual reduction in the lung CFUs from 28 
until 84  days postinfection, after which the INH alone group 
showed no significant decline to 112 days. In contrast, the CFUs 
continued to decline in the CC-11050 plus INH treatment group, 
reaching undetectable levels in the lungs of five out of six animals 
(P = 0.02) by 112 days postinfection (Figures 6A,B). Moreover, 
lung homogenates from infected mice treated with CC-11050 
FigUre 6 | Bacillary load in Mtb-infected mouse lungs with or without cc-11050 and/or inh treatment. (a) Bacterial CFUs at various time points in 
different treatment groups. Treatment was started at 14 days postinfection. *P = 0.07 between INH (triangle) and INH plus CC-11050-treated groups (diamond) 
(n = 6 per group per time point). (B) Individual data points at 112 days. One animal out of six from each of INH or INH plus CC-11050-treated groups had unusual 
CFU pattern that can be an outlier or due to technical error. Excluding these two samples from the analysis led to a significant difference in lung CFUs at 112 days 
postinfection between the two treatment groups (P = 0.02; n = 5 per group).
FigUre 5 | interaction and expression pattern of sDegs involved in canonical interferon signaling pathway in Mtb-infected mouse lungs with or 
without cc-11050 treatment. (a) Pathway map showing interaction of member genes involved in Ifn signaling pathway. Red color indicates upregulation, and 
green color indicates downregulation. (B) Intensity plot of SDEGs associated with Ifn signaling. UT, untreated; CC, treated with CC-11050. Red color shows 
upregulation, and blue color shows downregulation of gene expression. Scale bar ranges from +3 (red) to −3 (blue).
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plus INH yielded no detectable CFUs when plated on media con-
taining INH, indicating that PDE4 inhibition was not associated 
with the emergence of resistant organisms.
cc-11050 Plus inh Treatment reduces 
lung Pathology in Mtb-infected Mice
A morphometric analysis was carried out to compare the extent 
of pathology in the lungs of Mtb-infected mice in the different 
treatment groups (Figure 7). In the Mtb-infected untreated mice, 
the size (area) of granulomas at 28  days postinfection reached 
about 0.08 ± 0.059 mm2. At this time, significant differences in 
the lesion area were already noted between the untreated mice 
and those treated with INH alone (P = 0.0302) or with INH plus 
CC-11050 (P = 0.0259). By 112 days postinfection, a significant 
reduction in granuloma size was noted in the lungs of mice treated 
with INH, with or without adjunctive CC-11050, compared to 
the untreated group (P  =  0.008 and 0.0371, respectively, for 
FigUre 7 | Morphometric measurements of lung granulomas in 
Mtb-infected mice treated with cc-11050 (hatched bars), inh 
(horizontal bars), both (solid bars), or none (gray bars). *P = 0.0302 
between INH and no treatment; P = 0.0259 between INH plus CC-11050 
and no treatment at 28 days postinfection. *P = 0.008 and 0.0371, 
respectively, for INH and INH + CC-11050, compared to no treatment group 
(n = 4–6 per group per time point).
FigUre 8 | histology of Mtb-infected mouse lungs at 112 days 
postinfection. Representative image of H&E stained mouse lung sections at 
10× (a,c,e,g) and 40× (B,D,F,h) magnifications. (a,B) untreated; (c,D) 
CC-11050-treated; (e,F) INH-treated; and (g,h) INH plus CC-11050-treated. 
(a,c,e,g) are photographed at 10×, and (B,D,F,h) are photographed at 40× 
magnification. Note the presence of multiple, coalescent, and larger 
granulomas in the untreated and CC-11050-treated mouse lungs (a–D); in 
contrast, the INH-treated mouse had a smaller (e,F), while the INH plus 
CC-11050-treated animals had the smallest lung lesion (g,h).
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INH and INH plus CC-11050). Infected mice treated with INH 
plus CC-11050 had smaller lesions, compared to those treated 
with INH alone, although the difference was not statistically 
significant (Figure 7).
Histologic examination of the lungs also revealed differences 
in pathology between the treatment groups. At 28 days postinfec-
tion (14 days of treatment), the lungs of untreated mice showed 
diffuse granulomas (0.5–1 mm diameter), comprising aggregates 
of evenly dispersed macrophages and lymphocytes with few 
polymorphonuclear cells (Figures S3A,B in Supplementary 
Material). At this time, treatment with CC-11050 alone had no 
significant impact on the size and structure of the lesions, con-
firming that CC-11050 was not immune-suppressive (Figures 
S3C,D in Supplementary Material). In mice treated with INH 
alone (Figures S3E,F in Supplementary Material) or INH plus 
CC-11050 (Figures S3G,H in Supplementary Material), the 
lesions were somewhat smaller than those in the untreated or 
CC-11050-treated groups with much smaller areas of aggregated 
lymphoid cells. By 112 days postinfection, the relative extent of 
disease among the Mtb-infected untreated groups was similar 
to those observed at 28 days, although the granulomas showed 
a more structured cellular organization (Figure 8). In the lungs 
of untreated mice, the granulomas had condensed somewhat 
from the earlier time point and were beginning to coalesce 
(Figures  8A,B). These lesions contained small aggregates of 
macrophages with some scattered lymphocytes, surrounded by 
regions of more concentrated lymphoid cells. Treatment of the 
infected mice with CC-11050 alone did not result in significant 
differences in the immune cell composition of lung lesions from 
those seen in the untreated animals (Figures 8C,D). In contrast, 
the granulomas in the lungs of mice treated with INH alone 
were smaller and comprised mainly of lymphocytes surround-
ing small patches of macrophages at the center (Figures 8E,F). 
Treatment with CC-11050 plus INH resulted in fewer and more 
condensed lung lesions, compared to the other groups. These 
lesions were composed of densely packed lymphocytes with few 
interspersed macrophages (Figures 8G,H).
DiscUssiOn
Host-directed therapy shows promise as an adjunct to conven-
tional antibiotic treatment for TB to shorten the duration of 
chemotherapy and improve outcome (8, 18). The study described 
here extends our previous work demonstrating that selective 
immune modulation with a small molecule PDE4i, as an adjunct 
to the anti-TB drug INH, can reduce pathology and enhance anti-
microbial activity in the mouse model of pulmonary TB (11–13).
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In this study, we compared the impact of CC-11050 on TB 
treatment with our previous findings for CC-3052. Our results 
confirm and expand our previous observations and provide 
some information on the lung-specific PDE4 isoforms targeted 
by CC-11050. Previous reports have indicated that not all small 
molecule PDE4i drugs have the same capacity to improve TB 
chemotherapy (19–22). While rolipram and cilomilast treatment 
of Mtb-infected mice showed no impact on antibiotic-mediated 
bacillary clearance in the mouse pulmonary TB model (19), 
co-treatment of mice with roflumilast plus INH resulted in 
significantly reduced CFUs in the lungs, compared to INH alone 
(20), similar to our findings with CC-3052 and CC-11050. The 
variation in action of these molecules may reflect diversity in the 
enzyme specificities of the inhibitors. The family of PDE4 enzymes 
has 4 known subtypes (PDE4A–D) and at least 15 isotypes, which 
are differentially expressed in various tissue and cell types and 
differentially targeted by specific inhibitors (23). For example, the 
adverse gastrointestinal side effects, which limit pharmacologic 
use of rolipram, have been associated with specific splice-variant 
isoforms of Pde4D (21), while roflumilast appears to exert its 
anti-inflammatory effects mainly through PDE4B (22). In the 
present study, treatment with CC-11050 alone led to reduced 
transcript levels of Pde4D and Pde4Bi3 in the lungs, suggesting 
that these isoforms may be specifically targeted. However, our 
analysis did not distinguish between Pde4D splice-variants, and 
the effect of CC-11050 on these targets remains to be confirmed 
at the protein level.
The pharmacokinetic experiment revealed more rapid and 
greater absorption of CC-11050 in the mice than we observed in 
rabbits at the same dose of 50 mg/kg (Tmax and Cmax of 1,410 ng/ml 
and 2  h versus 163  ng/ml and 4  h, respectively) (14). These 
findings may reflect differences between rabbits and mice in 
gastrointestinal absorption, metabolism, tissue distribution, 
and/or excretion of the PDE4i. Coadministration of the PDE4i 
with INH to the mice resulted in a delay of the CC-11050 Tmax 
to 5  h, and a moderate increase in plasma Cmax and AUClast. 
These observations are likely explained by the well-documented 
inhibitory effects of INH on drug metabolism, mainly through 
its inhibition of several cytochrome P isoforms in the liver (24). 
In contrast, our previous study in rabbits showed no effects of 
INH on the pharmacokinetics of CC-11050 (14). Moreover, the 
PDE4i caused no significant changes in plasma levels of INH in 
co-treated rabbits. This observation may be relevant to the poten-
tial emergence of resistant bacilli when patients are treated with 
anti-TB drugs and adjunctive HDT. Of note, no INH-resistant 
bacilli have been recovered from any co-treated rabbits or mice 
in our investigations of PDE4i (11). Despite the differences in 
pharmacokinetics between the two animal models, the effects 
of CC-11050 on host gene expression and INH-mediated Mtb 
clearance were similar, supporting the likelihood for similar 
responses in humans. Taken together, the results of our studies in 
both the rabbit and mouse models provide a rationale for phase 
I clinical trials to establish appropriate dosing and determine 
the potential for drug–drug interactions between CC-11050 and 
antimicrobials in humans.
The GO analysis revealed that host cell processes associated 
with infectious disease, inflammatory response, and cellular 
function were among the most significantly affected biological 
functions in the untreated Mtb-infected mice. We observed a 
similar transcriptome profile in the lungs of Mtb-infected rab-
bits, in addition to significant changes in genes involved with 
lipid metabolism and small molecule transport (14). These 
additional biological functions may reflect differences between 
the physiological response of mice and rabbits to Mtb infec-
tion, particularly with regard to the formation of differentiated 
granulomas, which are seen in rabbits but not in mice (25). 
Mtb-infected mice develop lesions within the lungs, composed of 
immune cell aggregates with minimal structure and no hypoxia, 
which enlarge and coalesce over time. In contrast, rabbits show 
a progressive granulomatous response to Mtb infection, with 
highly structured hypoxic lesions surrounded by a fibrotic 
capsule. These lesions eventually liquefy and form open cavities, 
similar to the response seen in humans with pulmonary TB (25). 
Despite these differences, both models showed reduced signs of 
pathology in response to CC-11050 adjunctive treatment (14). 
This was demonstrated in mice by the reduced size in lung lesions 
of CC-11050 plus INH-treated animals. Additionally, MMP14 
and several genes in the fibrosis network, which were upregulated 
by infection, were downregulated to basal (uninfected) levels in 
response to CC-11050 treatment alone. Thus, despite the lack of 
visible fibrosis in the lungs of Mtb-infected mice, these animals 
displayed a gene expression profile in response to PDE4 inhibi-
tion that was consistent with the pathologic changes seen in 
Mtb-infected rabbits receiving the same treatment.
Although the rabbit model of pulmonary TB effectively mim-
ics the pathology of human disease, the rabbit genome has only 
been completed to 7× coverage, with roughly 80% of the genes 
annotated on the basis of predictions with limited functional 
validation (Broad Institute). For this reason, the mouse model 
provided a useful validation for our transcriptomic studies, par-
ticularly with regard to the early immune response to Mtb infec-
tion, which has been well studied in this animal. Genome-wide 
lung transcriptome analysis revealed dampened inflammatory 
response-associated network genes in CC-11050-treated mice. 
Specifically, several genes of the TNF-α, lung inflammation, Il-17, 
and Ifn signaling pathways/networks were upregulated in mouse 
lungs by Mtb infection; expression of most of these genes was 
significantly reduced by CC-11050 treatment.
Treatment of mice with CC-11050 plus INH led to a significant 
improvement in antibiotic-mediated bacillary clearance from the 
lungs, compared to INH alone. Similar to our previous results for 
CC-3052 in Mtb-infected mice, CC-11050 did not significantly 
affect the kinetics of bacillary clearance at early time points, 
whereas at later time points, when INH alone showed a plateau 
in Mtb killing, the PDE4i co-treated animals continued to show 
a decline in CFUs, reaching undetectable levels in 5/6 animals 
by 112  days postinfection. This alteration of the biphasic kill 
curve seen with INH alone is consistent with our hypothesis that 
modulation of the host innate immune response can lead to a 
reduction in the population of bacilli shifting into a physiologic 
state in which they are refractory to antibiotic killing (26). The 
association between host environmental pressure and antibiotic 
tolerance of Mtb was demonstrated in a recent study by Liu et al., 
where activation of Mtb-infected macrophages in vitro rendered 
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the bacilli tolerant to four first-line TB drugs, each of which was 
able to kill Mtb in resting macrophages (27). Transcriptional 
analysis of the intracellular bacilli revealed a common set of 
genes that were differentially expressed upon exposure to each of 
the four antibiotics. Moreover, the perturbations in the bacillary 
transcriptome caused by anti-TB drugs were strikingly similar to 
the profile of differentially expressed Mtb genes observed inside 
activated, compared to resting, macrophages (27). Thus, observa-
tions from the Liu et al., study suggest that the environmental 
pressure on Mtb within activated macrophages induces a stress 
response that renders the organisms tolerant to anti-TB drugs.
The safety of small molecule PDE4i as anti-inflammatory agents 
is an important consideration in the selection of these drugs for 
use in humans. Both mice and rabbits treated with CC-11050 or 
CC-3052 alone retained their ability to control Mtb growth as the 
infection progressed, indicating that adaptive immunity was not 
adversely affected. In contrast, uncontrolled bacillary replication 
in the lungs was a characteristic of generalized immune suppres-
sion, induced in mice by treatment with anti-TNF antibody or in 
rabbits treated with the soluble TNF receptor etanercept (11, 28).
Thus far, we have evaluated PDE4i in the context of treat-
ment of mice with a single anti-TB drug, INH. Because of the 
steep killing curve observed when infected mice are initially 
exposed to antibiotic, it may be difficult to see the additive effect 
of a second antibiotic. In contrast, the killing curve in rabbits, 
where the organisms are within fully differentiated granulomas, 
is much slower, providing an opportunity to evaluate the impact 
of CC-11050 on a multidrug regimen (14, 29). Consequently, we 
are evaluating the efficacy of CC-11050, provided as an adjunct, 
in combination with two first-line anti-TB drugs, INH plus RIF, 
in the rabbit model of pulmonary Mtb infection. Our prelimi-
nary results indicate that, after 8 weeks of treatment (starting at 
4 weeks postinfection), the combination of RIF plus INH shows 
enhanced bacillary killing compared to INH alone. Here, again, 
co-treatment of rabbits with CC-11050, together with INH and 
RIF, shows reduced CFUs in the lungs compared to INH and RIF 
alone. This study is currently in progress, and the results will be 
reported in a future publication.
In conclusion, the results of our present and published studies, 
conducted in both the mouse and rabbit models of pulmonary 
TB using two alternative inhibitors, provide proof-of-concept 
that adjunctive PDE4i significantly improves antibiotic-mediated 
bacterial killing and reduces lung pathology and is a promising 
candidate drug for HDT to improve treatment of humans with 
pulmonary TB.
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FigUre s1 | structure of cc-11050 (a) and plasma levels of cc-11050 at 
various time points up to 24 h in uninfected mouse treated with various 
concentrations (B).
FigUre s2 | Validation of microarray data by qPcr. Randomly selected 
mouse genes from microarray data at 28 days postinfection was evaluated by 
qPCR. Values shown are expression levels in CC-11050-treated mouse lungs, 
compared to the untreated. Level of Gapdh expression was used to normalize 
the data. The experiment was repeated in duplicate with four samples per 
group. *P < 0.05; **P < 0.001.
FigUre s3 | histology of mouse lung at 28 days postinfection. 
Representative images of mouse lung sections at 28 days postinfection 
(14 days posttreatment), stained with H & E, showing the architecture of 
granulomas with diffuse accumulation of inflammatory/immune cells. (a,B) 
untreated; (c,D) CC-11050-treated; (e,F) INH-treated; (g,h) INH plus 
CC-11050-treated. (a,c,e,g) are photographed at 10×, and (B,D,F,h) are 
photographed at 40× magnification. Note that the granulomas in INH or INH 
plus CC-11050-treated mouse lungs are smaller than the untreated or those 
treated with CC-11050 alone.
TaBle s1 | list of sDegs associated with TnF-α, lung inflammation, 
il-17, and ifn signaling networks/pathways.
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